PCVX analyst estimates
Vaxcyte (PCVX) analyst ratings, the average price target and its range, and every firm's latest call.
PCVX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | Vaxcyte (PCVX) PT Set at $120 at Cantor Fitzgerald - Pressure on Shares Explained by Challenging Market | $120.00 |
| Oct 5, 2026 | Guggenheim | Vaxcyte (PCVX) PT Raised to $125 at Guggenheim | $125.00 |
| Oct 5, 2026 | Needham | Vaxcyte price target raised to $122 from $110 at Needham | $122.00 |
| Feb 25, 2026 | BTIG | Vaxcyte (PCVX) PT Raised to $89 at BTIG | $89.00 |
| Nov 19, 2025 | Leerink Partners | Vaxcyte (PCVX) PT Raised to $77 at Leerink Partners | $77.00 |
| Nov 6, 2024 | Leerink Partners | Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX) | $135.00 |
| Nov 6, 2024 | Jefferies | Vaxcyte (PCVX) PT Raised to $146 at Jefferies | $146.00 |
| Sep 10, 2024 | Mizuho Securities | Vaxcyte price target raised to $163 from $113 at Mizuho | $163.00 |
| Sep 4, 2024 | Bank of America Securities | Vaxcyte price target raised to $140 from $101 at BofA | $140.00 |
| Sep 3, 2024 | Mizuho Securities | Mizuho Reiterates Outperform Rating on Vaxcyte (PCVX) | $113.00 |
| Sep 3, 2024 | Jefferies | Vaxcyte (PCVX) PT Raised to $129 at Jefferies | $129.00 |
| Sep 3, 2024 | BTIG | Vaxcyte (PCVX) PT Raised to $160 at BTIG | $160.00 |
| Sep 3, 2024 | Leerink Partners | Vaxcyte price target raised to $153 at Leerink after VAX-31 'home run' | $153.00 |
| Aug 7, 2024 | BTIG | BTIG Reiterates Buy Rating on Vaxcyte (PCVX) | $98.00 |
| Jan 3, 2023 | Needham | Needham Maintains Buy on Vaxcyte, Raises Price Target to $58 | $58.00 |
- 5 firms rate PCVX: 5 buy, 0 hold, 0 sell.
- The average price target is $122.33 from 3 analysts, from $120.00 to $125.00.
Updated 2026-11-02 23:59 UTC